



<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)			<b>COMPLETE IF KNOWN</b>		
			Application Number	10/730,704	
			Filing Date	December 8, 2003	
			First Named Inventor	R.P. Nargund et al.	
			Group Art Unit	-- 1614	
			Examiner Name	SPINACK	
Sheet	1	of	5	Attorney Docket Number	21151

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code (if known)		
PS		2002/0006964		YOUNG et al.	01/17/2002
DS		6,335,345		BANYU PHARMACEUTICAL Co., Ltd.	01/01/2002
PS		4,929,629		BOOTS COMPANY, PLC	05/29/1990
PS		5,436,272		THE BOOTS COMPANY (USA), Inc.	07/25/1995
PS		4,746,680		THE BOOTS COMPANY, PLC	05/24/1988
PS		6,258,837		BANYU PHARMACEUTICAL Co., Ltd.	07/10/2001
PS		6,344,481		PFIZER Inc.	02/05/2002
PS		6,344,474		SANOFI-SYNTHELABO	02/05/2002
PS		2002/0010192		COE et al.	01/24/2002
PS		2002/0091114		PIOT-GROSJEAN et al.	07/11/2002
PS		5,908,830		MERCK & CO., Inc.	06/01/1999
PS		6,258,837		BANYU PHARMACEUTICAL Co., Ltd.	07/10/2001
PS		2002/0062022		AMERICAN HOME PRODUCTS CORPORATION	05/23/2002

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No.	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office	Number Kind Code (if known)		
PS			EP 0 920 864	PFIZER PRODUCTS INC.	06/09/1999
PS			WO 00/66578	PFIZER PRODUCTS INC.	11/09/2000
PS			WO 97/46250	SYNAPTIC PHARMACEUTICAL CORP.	12/11/1997
PS			WO 97/16189	MERCK & CO., Inc.	05/09/1997
PS			WO 96/40912	AMGEN Inc.	12/19/1996
PS			WO 97/06816	AMGEN Inc.	02/27/1997
PS			WO 97/18833	AMGEN Inc.	05/29/1997
PS			WO 98/28427	AMGEN Inc.	07/02/1998
PS			WO 02/060427	SEPRACOR Inc.	08/08/2002
PS			WO 02/060428	SEPRACOR Inc.	08/08/2002
Examiner Signature		P. Spinack		Date Considered	9/17/06

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 09/05/2003

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE

### STATEMENT BY APPLICANT

*(use as many sheets as necessary)*

**COMPLETE IF KNOWN**

<b>Application Number</b>	10/730,704
<b>Filing Date</b>	December 8, 2003
<b>First Named Inventor</b>	R.P. Nargund et al.
<b>Group Art Unit</b>	--
<b>Examiner Name</b>	
<b>Attorney Docket Number</b>	21151

Sheet

2

of

5

Attorney Docket Number 21151

## U.S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office	Number  (if known)		
PS			WO 00/76493	NAJARIAN	12/21/2000
PS			WO 01/52825	NOVARTIS-ERFINDUNGEN VERWALTUNGSGESELLSCHAFT M.B.H.	07/26/2001
PS			WO 01/01969	ENDORECHERCHE, INC.	01/11/2001
PS			WO 02/32897	PFIZER PRODUCTS INC.	04/25/2002
PS			WO 98/18481	MERCK & CO., Inc.	05/07/1988
PS			WO 02/068388	MERCK & CO., Inc.	09/06/2002
PS			WO 02/019998	ELI LILLY AND COMPANY	03/14/2002
PS			WO 98/32441	SANOFI	07/30/1998
PS			WO 02/28346	AVENTIS PHARMA S.A.	04/11/2002

**Examiner  
Signature**

Date  
Considered

9/17/06

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.**

Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 09/05/2003

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE</b>  <b>STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>			<b>COMPLETE IF KNOWN</b>		
			Application Number	10/730,704	
			Filing Date	December 8, 2003	
			First Named Inventor	R.P. Nargund et al.	
			Group Art Unit	--	
			Examiner Name		
Sheet	3	of	5	Attorney Docket Number	21151

NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
PS	AA	Farrigan et al., Nature Reviews - Drug Discovery, Vol. 1 (2002), "Obesity market overview", pp. 257-258,
PS	AB	Bray et al., Obesity Research, Vol. 7 (1999), "Sibutramine produces dose-related weight loss", pp. 189-198,
PS	AC	Kopelman, Nature, Vol. 404 (2000), "Obesity as a medical problem", pp. 635-643,
PS	AD	Steinbeck, Internal Medicine Journal (2002), Vol. 32, "Obesity: the science behind the management", pp. 237-241,
PS	AE	Qu et al., Nature, Vol. 380 (1996), "A role for melanin-concentrating hormone in the central regulation of feeding behaviour", pp. 243-247,
PS	AF	Davidson et al., JAMA, Vol. 281 (1999), "Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat", pp. 235-242,
PS	AG	Douglas et al., Int'l J. of Obesity, Vol. 7 (1983), "Plasma phentermine levels, weight loss and side-effects", pp. 591-595,
PS	AH	Guy-Grand et al., The Lancet (1989), "Therapeutics: International trial of long-term dexfenfluramine in obesity", pp. 1142-1144,
PS	AI	Muccioli et al., Eur. J. of Pharmacol., Vol. 440 (2002), "Neuroendocrine and peripheral activities of ghrelin...", pp. 235-254,
PS	AJ	Chamorro et al., Int'l J. of Obesity, Vol. 26 (2002), "Appetite suppression based on selective inhibition of NPY receptors", pp. 281-298,
PS	AK	Balasubramaniam, The American J. of Surgery, Vol. 183 (2002), "Clinical potentials of neuropeptide Y family or hormones", pp. 430-434,
PS	AL	Guercioli, Int'l J. of Obesity, Vol. 21 (1997), Suppl. 3, "Mode of action of orlistat", pp. S12-S23,
PS	AM	Sletten et al., Current Therap. Res., Vol. 9 (1967), "Weight reduction with chlorphentermine and phenmetrazine in obese psychiatric patients during chlorpromazine therapy", pp. 570-575,
PS	AN	Kolakowska et al., Int'l Clinical Psychopharmacol., Vol. 2 (1987), "An open clinical trial of fenfluramine in chronic schizophrenia: A pilot study", pp. 83-88,
PS	AO	Pierson et al., J. Med. Chem., Vol. 40 (1997), "Synthesis and biological evaluation of potent, selective, hexapeptide CCK-A agonist anorectic agents", pp. 4302-4307,

Examiner Signature	<i>P. Spivack</i>	Date Considered	9/17/06
--------------------	-------------------	-----------------	---------

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 09/03/2003

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE</b> <b>STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>			<b>COMPLETE IF KNOWN</b>		
			Application Number	10/730,704	
			Filing Date	December 8, 2003	
			First Named Inventor	R.P. Nargund et al.	
			Group Art Unit	--	
			Examiner Name		
Sheet	4	of	5	Attorney Docket Number	21151

NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
PS	AP	Bray et al., Nature, Vol. 404 (2000), "Medicinal strategies in the treatment of obesity", pp. 672-677
PS	AQ	Kushner et al., Current Opinion in Gastroenterology, Vol. 18 (2002), "Obesity pharmacology: past, present, and future, pp. 213-220
PS	AR	MacNeil et al., Eur. J. of Pharmacol., Vol. 440 (2002), "The role of melanocortins in body weight regulation...", pp. 141-157.
PS	AS	Kirkham et al., Psychopharmacology, Vol. 153 (2001), "Synergistic effects ( <i>sic</i> ) of opioid and cannabinoid antagonists", pp. 267-270
PS	AT	Boozar et al., Metabolism, Vol. 50 (2001), "Synergy of sibutramine and low-dose leptin in treatment of diet-induced obesity in rats", pp 889-893.
PS	AU	Wadden et al., Obesity Research, Vol. 8 (2000), "Effects of sibutramine plus orlistat in obese women following 1 year of treatment ...., pp. 431-437
PS	AV	Zhou et al., Society for Neuroscience Abstracts, Vol. 27 (2001), 31st annual meeting of the Society for Neuroscience, San Diego, CA, November 10-15, 2001, "Attenuation of withdrawal reaction by a selective melanocortin MC4 receptor antagonist ...", p. 599
PS	AW	Myrick et al., The American J. on Addictions, Vol. 10 (2001), "New developments in the pharmacotherapy of alcohol dependence", pp. 3-15.
PS	AX	Angehelescu et al., J. of Clin. Psychopharmacol., Vol. 22 (2000), "Add-on combination and maintenance treatment ...., pp. 521-524.
PS	AY	Matson et al., Am. J. Physiol. Regulatory Integrative Comp. Physiol., Vol. 278 (2000), "Cholecystokinin and leptin act synergistically to reduce body weight", pp. R882-R890
PS	AZ	Le et al., Alcohol & Alcoholism, Vol. 31 (1996), "Use of serotonin (5-HT) and opiate-based drugs in the pharmacotherapy of alcohol dependence ...", pp. 27-32.
PS	BA	Chiesi et al., TRENDS in Pharmacological Sciences, Vol. 22 (2001), "Pharmacotherapy of obesity: targets and perspectives", pp 247-254.
PS	BB	Atkinson et al., Obesity Research, Vol. 3 (1995), "Combined drug treatment of obesity", pp. 497S-500S.
PS	BC	Raffa et al., Am. J. Med., Vol. 101, Suppl. 1A (1996), "A novel approach to the pharmacology of analgesics", pp. 40S-46S
PS	BD	Fernandez-Lopez et al., Drugs, Vol. 62 (2002), "Pharmacological approaches for the treatment of obesity", pp. 915-944

Examiner Signature	P. Spawack	Date Considered	9/17/06
--------------------	------------	-----------------	---------

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 09/05/2003

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE</b>  <b>STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>			<b>COMPLETE IF KNOWN</b>		
			Application Number	10/730,704	
			Filing Date	December 8, 2003	
			First Named Inventor	R.P. Nargund et al.	
			Group Art Unit	--	
			Examiner Name		
Sheet	5	of	5	Attorney Docket Number	21151

NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
PS	BE	Lu et al., Peptides, Vol. 21 (2000), "Leptin resistance in obesity is characterized by decreased sensitivity to proopiomelanocortin products", pp. 1479-1485 -
PS	BF	Dunbar et al., Brain Research Bulletin, Vol. 50 (1999), "Leptin-induced increase in sympathetic nervous and cardiovascular tone is mediated by proopiomelanocortin (POMC) products", pp. 215-221 .
PS	BG	Bickerdike et al., Eur. J. of Pharmacology, Vol. 271 (1994), "The influence of 5-hydroxytryptamine re-uptake blockade on CCK receptor antagonist effects in the rat elevated zero-maze", pp. 403-411 .
PS	BH	Proietto et al., Exp. Opin. Invest. Drugs, Vol. 9 (2000), "Novel anti-obesity drugs", pp. 1317-1326,
PS	BI	Parker et al., Eur. J. of Pharmacology, Vol. 440 (2002), "Neuropeptide Y receptors as targets for anti-obesity drug development ...", pp. 173-187,
PS	BJ	Rowland et al., Psychopharmacology, Vol. 159 (2001), "Effects of the cannabinoid receptor antagonist SR 141716, alone and in combination with dexfenfluramine ...", pp. 111-116 .
PS	BK	Sabath Silva et al., Revista de Investigacion Clinica, Vol. 54 (2002), "Leptina", pp. 161-165 .
PS	BL	Chaki et al., Exp. Opin. Ther. Patents, Vol. 11 (2001), "Recent advances in feeding suppressing agents...", pp. 1677-1692 .
PS	BM	Pomonis et al., The J. of Neuroscience, Vol. 17 (1997), "Interaction of the hypothalamic paraventricular nucleus and central nucleus of the amygdala in naloxone blockade ...", pp. 5175-5182 .
PS	BN	Lalonde et al, Physiol. & Behavior, Vol. 80 (2004), "Additive effects of leptin and topiramate in reducing fat deposition in lean and obese ob/ob mice", pp. 415-420 .
PS	BO	Turton et al., Nature, Vol. 379 (1996), "A role for glucagon-like peptide-1 in the central regulation of feeding", pp. 69-72 .
PS	BP	Erickson et al., Nature, Vol. 381 (1996), "Sensitivity to leptin and susceptibility to seizures of mice lacking neuropeptide Y", pp.; 415-418 ,
PS	BQ	Lonnqvist et al., Nature Medicine, Vol. 1 (1995), "Overexpression of the obese (ob) gene in adipose tissue of human obese subjects", pp 950-953 .
PS	BR	De Vos et al., J. of Biol. Chem., Vol. 270 (1995), "Induction of ob gene expression by corticosteroids is accompanied by body weight loss and reduced food intake", pp. 15958-15961,

Examiner Signature	<i>P. Spivack</i>	Date Considered	9/17/06
--------------------	-------------------	-----------------	---------


\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 09/05/2003

*(use as many sheets as necessary)*

**COMPLETE IF KNOWN**

<b>Application Number</b>	10/730,704
<b>Filing Date</b>	December 8, 2003
<b>First Named Inventor</b>	Ravi P. Nargund et al.
<b>Group Art Unit</b>	1614
<b>Examiner Name</b>	P.G. Spivack
<b>Attorney Docket Number</b>	21151



1

of

2

Attorney Docket Number 21151

[illegible]

Examiner Initials*	Cite No.	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office	Number Kind Code (if known)		
PS PS PS PS PS PS		WO 02/20488		F. Hoffman-La Roche AG	03/14/2002
		WO 02/38551		F. Hoffman-La Roche AG	05/16/2002
		WO 02/22592		Schering Corporation	03/21/2002
		WO 02/49648		Schering Corporation	06/27/2002
		WO 03/007887		Merck & Co., Inc.	01/30/2003
		WO 2004/058741		Merck & Co., Inc.	07/15/2004

P. Spivack

Date Considered

9/17/06

**SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.**

Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 7/12/2005

Substitute for form 14498/PTO

## INFORMATION DISCLOSURE

### STATEMENT BY APPLICANT

(use as many sheets as necessary).

**COMPLETE IF KNOWN**

<b>Application Number</b>	10/730,704
<b>Filing Date</b>	December 8, 2003
<b>First Named Inventor</b>	Ravi P. Nargund et al.
<b>Group Art Unit</b>	1614
<b>Examiner Name</b>	P.G. Spivack
<b>Attorney Docket Number</b>	21151

Sheet	2	of	2	Attorney Docket Number	21151
-------	---	----	---	------------------------	-------

## NON PATENT LITERATURE DOCUMENTS

[illegible]

Examiner Signature	P. Spindick	Date Considered	4/17/06
--------------------	-------------	-----------------	---------

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.**

Computer generated form \* IDS Form\* (IDS Folder), Merck & Co., Inc., -7/12/2005